2 weeks Ago By ABMN Staff
Research analysts at Evercore ISI initiated coverage on shares of Quest Diagnostics ( NYSE:DGX – Get Free Report ) in a research note issued to investors on Wednesday, Marketbeat.com reports. The brokerage set an “in-line” rating and a $165.
00 price target on the medical research company’s stock. Evercore ISI’s target price indicates a potential upside of 5.61% from the stock’s current price.
A number of other research analysts have also issued reports on the company. Barclays boosted their price target on Quest Diagnostics from $144.00 to $154.
00 and gave the stock an “equal weight” rating in a research report on Tuesday. Truist Financial boosted their price target on shares of Quest Diagnostics from $150.00 to $158.
00 and gave the stock a “hold” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. increased their price objective on shares of Quest Diagnostics from $152.
00 to $155.00 and gave the company a “neutral” rating in a report on Thursday, May 30th. Piper Sandler upped their target price on Quest Diagnostics from $145.
00 to $150.00 and gave the stock a “neutral” rating in a research report on Monday, July 29th. Finally, Robert W.
Baird upped their price objective on Quest Diagnostics from $153.00 to $154.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th.
Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $154.33.
Read Our Latest Analysis on Quest Diagnostics Quest Diagnostics Stock Up 0.9 % Quest Diagnostics ( NYSE:DGX – Get Free Report ) last issued its earnings results on Tuesday, July 23rd. The medical research company reported $2.
35 earnings per share for the quarter, topping the consensus estimate of $2.31 by $0.04.
The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.39 billion.
Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%.
The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same period last year, the company earned $2.
30 earnings per share. Analysts predict that Quest Diagnostics will post 8.89 EPS for the current year.
Insider Activity In other news, SVP Mark E. Delaney sold 420 shares of the stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $143.
08, for a total value of $60,093.60. Following the completion of the sale, the senior vice president now directly owns 5,019 shares of the company’s stock, valued at $718,118.
52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website . In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 1,990 shares of the company’s stock in a transaction dated Wednesday, August 28th.
The stock was sold at an average price of $153.26, for a total value of $304,987.40.
Following the transaction, the senior vice president now directly owns 11,459 shares of the company’s stock, valued at approximately $1,756,206.34. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website .
Also, SVP Mark E. Delaney sold 420 shares of Quest Diagnostics stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.
08, for a total value of $60,093.60. Following the sale, the senior vice president now owns 5,019 shares of the company’s stock, valued at $718,118.
52. The disclosure for this sale can be found here . 0.
79% of the stock is currently owned by corporate insiders. Hedge Funds Weigh In On Quest Diagnostics Hedge funds have recently bought and sold shares of the business. Cetera Investment Advisers grew its holdings in Quest Diagnostics by 1.
5% during the second quarter. Cetera Investment Advisers now owns 16,125 shares of the medical research company’s stock valued at $2,207,000 after purchasing an additional 243 shares during the last quarter. Brandes Investment Partners LP boosted its holdings in Quest Diagnostics by 38.
8% during the second quarter. Brandes Investment Partners LP now owns 8,297 shares of the medical research company’s stock valued at $1,136,000 after acquiring an additional 2,320 shares during the period. Quarry LP acquired a new stake in shares of Quest Diagnostics in the second quarter valued at about $74,000.
Sunbelt Securities Inc. bought a new position in shares of Quest Diagnostics in the second quarter worth about $40,000. Finally, Wellington Wealth Strategies LLC.
acquired a new position in shares of Quest Diagnostics during the 2nd quarter worth about $294,000. 88.06% of the stock is owned by institutional investors and hedge funds.
Quest Diagnostics Company Profile ( Get Free Report ) Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. See Also Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.
com's FREE daily email newsletter ..
